These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 35719927)

  • 1. The Molecular Role of IL-35 in Non-Small Cell Lung Cancer.
    Hao Y; Dong H; Li W; Lv X; Shi B; Gao P
    Front Oncol; 2022; 12():874823. PubMed ID: 35719927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does the Combined Use of Aspirin and Immunotherapy Result in Better Outcomes in Non-Small Cell Lung Cancer Than Immunotherapy Alone?
    Aiad M; Tahir A; Fresco K; Prenatt Z; Ramos-Feliciano K; Walia J; Stoltzfus J; Albandar HJ
    Cureus; 2022 Jun; 14(6):e25891. PubMed ID: 35720783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

  • 4. Th17 cell-derived IL-17A promoted tumor progression via STAT3/NF-κB/Notch1 signaling in non-small cell lung cancer.
    Wang R; Yang L; Zhang C; Wang R; Zhang Z; He Q; Chen X; Zhang B; Qin Z; Wang L; Zhang Y
    Oncoimmunology; 2018; 7(11):e1461303. PubMed ID: 30377557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disturbed Th17/Treg Balance in Patients with Non-small Cell Lung Cancer.
    Duan MC; Han W; Jin PW; Wei YP; Wei Q; Zhang LM; Li JC
    Inflammation; 2015 Dec; 38(6):2156-65. PubMed ID: 26077695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
    Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
    Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies.
    To KKW; Fong W; Cho WCS
    Front Oncol; 2021; 11():635007. PubMed ID: 34113560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased expression of the immunosuppressive interleukin-35 in patients with non-small cell lung cancer.
    Heim L; Kachler K; Siegmund R; Trufa DI; Mittler S; Geppert CI; Friedrich J; Rieker RJ; Sirbu H; Finotto S
    Br J Cancer; 2019 Apr; 120(9):903-912. PubMed ID: 30956278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of PD-1/L1 inhibitors in brain metastases of non-small-cell lung cancer: pooled analysis from seven randomized controlled trials.
    Li W; Jiang J; Huang L; Long F
    Future Oncol; 2022 Jan; 18(3):403-412. PubMed ID: 34787500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed Cell Death Ligand 1 Expression in Resected Non-Small Cell Lung Cancer.
    Yu H; Brustugun OT; Ekman S; Botling J; La Fleur L; Micke P; Solberg S; Berglund A; Rivard C; Hirsch FR
    Clin Lung Cancer; 2021 Jul; 22(4):e555-e562. PubMed ID: 33214079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: Mechanisms, advances, and challenges.
    Zhou S; Xie J; Huang Z; Deng L; Wu L; Yu J; Meng X
    Cancer Lett; 2021 Apr; 502():166-179. PubMed ID: 33450361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour necrosis factor, interferon-gamma and interleukins as predictive markers of antiprogrammed cell-death protein-1 treatment in advanced non-small cell lung cancer: a pragmatic approach in clinical practice.
    Boutsikou E; Domvri K; Hardavella G; Tsiouda D; Zarogoulidis K; Kontakiotis T
    Ther Adv Med Oncol; 2018; 10():1758835918768238. PubMed ID: 29662549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
    Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
    J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt.
    Bahnassy AA; Ismail H; Mohanad M; El-Bastawisy A; Yousef HF
    J Egypt Natl Canc Inst; 2022 May; 34(1):23. PubMed ID: 35644823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival Impact of Aggressive Treatment and PD-L1 Expression in Oligometastatic NSCLC.
    Gauvin C; Krishnan V; Kaci I; Tran-Thanh D; Bédard K; Albadine R; Leduc C; Gaboury L; Blais N; Tehfe M; Routy B; Florescu M
    Curr Oncol; 2021 Jan; 28(1):593-605. PubMed ID: 33498159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced NSCLC patients with high IL-6 levels have altered peripheral T cell population and signaling.
    Rice SJ; Liu X; Zhang J; Jia B; Zheng H; Belani CP
    Lung Cancer; 2019 May; 131():58-61. PubMed ID: 31027698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review.
    Brody R; Zhang Y; Ballas M; Siddiqui MK; Gupta P; Barker C; Midha A; Walker J
    Lung Cancer; 2017 Oct; 112():200-215. PubMed ID: 29191596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.